ACUS:Acusphere, Inc. has been a strange story. . Wall Street doesn't think the company's drug Imagify is going to get approved. Yet, doctors are excited about the drug, and think it will be used as soon as it is approved...In the meantime, cash burn is a concern and management is going to have to figure out how to raise money yet again in 2008. So who's right? The stock is currently under $1.50 a share. Is it time for a speculative play?
2 comments:
Absolutely time to take a big bite of this small cap. Think about this, at the last dilution an institutional investor bought 20 million dollars worth at $2.60!
We publish a site for the cardiovascular ultrasound industry.
You may find other stories & companies worth note at our site.
http://www.echochief.com/echochief_contrast_agents.php
Post a Comment